Tarsus (TARS) raises 2026 guidance as XDEMVY sales jump nearly 64%
Tarsus reported Q3 XDEMVY sales up nearly 64% year on year to $194.6 million and raised its FY 2026 sales guidance, citing record prescriptions.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, third-quarter sales of XDEMVY rose nearly 64% year on year to $194.6 million. The company pointed to record prescriptions and lifted its sales guidance for fiscal 2026.
Tarsus holds cash of about $310 million. The company plans to use it to support pipeline investment, including several near-term clinical milestones.
why it matters
For investors, the key point is that the commercial product is gaining momentum, and the higher guidance backs up the sales trend. Roughly $310 million in cash gives the company room to fund its clinical programs.
market impact
Shares of TARS: record sales and higher guidance support interest in the stock
- TARS shares pressure up — strong XDEMVY sales growth and higher 2026 guidance support demand
tags
instruments
sources
- TARS: Record XDEMVY growth lifted FY 2026 guidance as pipeline programs advanced — TradingView, 3 November 2026 at 23:42 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗